Higher detection rate of JAK2 mutation using plasma.

作者信息

Ma Wanlong, Kantarjian Hagop, Zhang Xi, Sun Weimin, Buller Arlene M, Jilani Iman, Schwartz Joyce G, Giles Francis, Albitar Maher

出版信息

Blood. 2008 Apr 1;111(7):3906-7. doi: 10.1182/blood-2008-02-139188.

DOI:10.1182/blood-2008-02-139188

PMID:18362222

Abstract

摘要

相似文献

Higher detection rate of JAK2 mutation using plasma.

Blood. 2008 Apr 1;111(7):3906-7. doi: 10.1182/blood-2008-02-139188.

Plasma quantitation of JAK2 mutation is not suitable as a clinical test: an artifact of storage.

Blood. 2009 Jul 2;114(1):223-4; author reply 224. doi: 10.1182/blood-2009-03-209593.

Detection of the JAK2 mutation in myeloproliferative neoplasms by asymmetric PCR with unlabeled probe and high-resolution melt analysis.

J Clin Lab Anal. 2011;25(4):300-4. doi: 10.1002/jcla.20474.

Comparison of whole blood vs purified blood granulocytes for the detection and quantitation of JAK2(V617F).

Leukemia. 2007 May;21(5):1128-30. doi: 10.1038/sj.leu.2404588. Epub 2007 Feb 15.

Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias.

J Mol Diagn. 2009 Jan;11(1):49-53. doi: 10.2353/jmoldx.2009.080114. Epub 2008 Dec 12.

Plasma levels of JAK2 mRNA in patients with chronic myeloproliferative diseases with and without V617F mutation: implications for prognosis and disease biology.

Int J Lab Hematol. 2010 Feb;32(1 Pt 2):95-102. doi: 10.1111/j.1751-553X.2009.01140.x. Epub 2009 Feb 25.

Analysis of JAK3, JAK2, and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome.

Blood. 2007 Aug 1;110(3):1077-9. doi: 10.1182/blood-2007-03-080374.

MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders.

Diagn Mol Pathol. 2011 Mar;20(1):34-9. doi: 10.1097/PDM.0b013e3181ecd261.

MassARRAY assay: a more accurate method for JAK2V617F mutation detection in Chinese patients with myeloproliferative disorders.

Leukemia. 2008 Mar;22(3):660-3. doi: 10.1038/sj.leu.2404931. Epub 2007 Aug 30.

Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR.

Ann Hematol. 2016 Apr;95(5):739-44. doi: 10.1007/s00277-016-2623-0. Epub 2016 Mar 1.

引用本文的文献

Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors.

Oncotarget. 2017 Mar 14;8(11):17936-17944. doi: 10.18632/oncotarget.15316.

Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.

Curr Cancer Drug Targets. 2011 Mar;11(3):254-84. doi: 10.2174/156800911794519716.

Ubiquitin-proteasome system profiling in acute leukemias and its clinical relevance.

Leuk Res. 2011 Apr;35(4):526-33. doi: 10.1016/j.leukres.2010.09.009. Epub 2010 Oct 15.

Recent advances in the diagnosis and classification of myeloid neoplasms--comments on the 2008 WHO classification.

Int J Lab Hematol. 2010 Oct;32(5):461-76. doi: 10.1111/j.1751-553X.2010.01246.x. Epub 2010 Jul 7.

Detection of exon 12 Mutations in the JAK2 gene: enhanced analytical sensitivity using clamped PCR and nucleotide sequencing.

J Mol Diagn. 2010 May;12(3):278-82. doi: 10.2353/jmoldx.2010.090177. Epub 2010 Mar 4.

Comparison of JAK2V617F mutation assessment employing different molecular diagnostic techniques.

Blood Transfus. 2009 Jul;7(3):204-9. doi: 10.2450/2009.0070-08.

Plasma quantitation of JAK2 mutation is not suitable as a clinical test: an artifact of storage.

Blood. 2009 Jul 2;114(1):223-4; author reply 224. doi: 10.1182/blood-2009-03-209593.

Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome.

Clin Cancer Res. 2009 Jun 1;15(11):3820-6. doi: 10.1158/1078-0432.CCR-08-3034. Epub 2009 May 19.

Plasma levels of JAK2 mRNA in patients with chronic myeloproliferative diseases with and without V617F mutation: implications for prognosis and disease biology.

Int J Lab Hematol. 2010 Feb;32(1 Pt 2):95-102. doi: 10.1111/j.1751-553X.2009.01140.x. Epub 2009 Feb 25.

Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias.

J Mol Diagn. 2009 Jan;11(1):49-53. doi: 10.2353/jmoldx.2009.080114. Epub 2008 Dec 12.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验